Eligibility Module

Eligibility Module

The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.

Eligibility Module path is as follows:

Study -> Protocol Section -> Eligibility Module

Eligibility Module


Ignite Creation Date: 2025-12-24 @ 6:38 PM
Ignite Modification Date: 2025-12-24 @ 6:38 PM
NCT ID: NCT01780857
Eligibility Criteria: Inclusion Criteria: * Subjects must give written informed consent. * Subjects are age 18 years or older, with a diagnosis of palmoplantar pustulosis (PPP) or be a healthy control. * Subjects must be able to adhere to the study visit schedule and other protocol requirements. * Patient must be off systemic psoriasis therapies (e.g. retinoids, phototherapy, methotrexate, cyclosporine etc.) for at least 4 weeks, biologic therapies for 12 weeks (or 24 weeks in the case of ustekinumab) and off topical therapies (e.g. calcipotriene, topical steroids) for at least 2 weeks. Exclusion Criteria: * Inability to provide informed consent. * Patient is unwilling to be off systemic psoriasis therapies for at least 4 weeks, biologic therapies for 12 weeks (or 24 weeks in the case of ustekinumab) or off topical therapies for at least 2 weeks. * Unwilling to consent to skin biopsy or blood draw. * Are pregnant, nursing, or planning a pregnancy while enrolled in the study. * Uncontrolled medical conditions (diabetes, liver disease, renal disease). * Have a history of latent or active granulomatous infection, including histoplasmosis or coccidioidomycosis, prior to screening or have had a non-tuberculous mycobacterial infection or opportunistic infection (e.g., cytomegalovirus, pneumocystosis, aspergillosis) within 6 months prior to screening.
Healthy Volunteers: True
Sex: ALL
Minimum Age: 18 Years
Maximum Age: 80 Years
Study: NCT01780857
Study Brief:
Protocol Section: NCT01780857